Get the Stockscreener App
1.61
2.55%
0.04
After Hours:
1.60
-0.01
-0.62%
Okyo Pharma Limited stock is traded at $1.61, with a volume of 7,260.
It is up +2.55% in the last 24 hours and down -0.62% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.57
Open:
$1.57
24h Volume:
7,260
Relative Volume:
0.11
Market Cap:
$84.49M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-12.84
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
+5.92%
1M Performance:
-0.62%
6M Performance:
-24.06%
1Y Performance:
-42.09%
1-Day Range:
$1.57
$1.6218
1-Week Range:
$1.46
$1.6218
52-Week Range:
$1.42
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.61 | 78.72M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
Price to book forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Price to earnings forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBITDA forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to revenue forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – BOATS:OKYO - TradingView
OKYO Pharma Limited Actuals & Estimates (NASDAQ:OKYO) - TradingView
OKYO Pharma Ltd (OKYO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OKYO Pharma And The Small-Cap Eye Care Story - Kalkine Media
OKYO Pharma Ltd (OKYO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3 - Stock Titan
OKYO Pharma (OKYO) director awarded options on 3,500 common shares - Stock Titan
OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85 - Stock Titan
Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares - Stock Titan
OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85 - Stock Titan
OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners - Stock Titan
OKYO Pharma Slips 1.85% as Shares Test Key Support LevelTrend Following Picks - newsline.com
OKYO Pharma (OKYO) Retreats Toward Support as Biotech Sector Faces HeadwindsInverse ETF Flow - newsline.com
OKYO Pharma (OKYO) director reports detailed stock option grants - Stock Titan
OKYO H2'25 Earnings: EPS estimate is (0.08) USD - TradingView
OKYO Pharma (OKYO) director discloses stock and option holdings - Stock Titan
[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership - Stock Titan
OKYO Pharma Edges Lower, Holds Steady Near Key Support LevelStop Loss Guidance - newsline.com
OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma (OKYO) Edges Higher on Modest Gains, Holds Above Key SupportSentiment Divergence - The Legal Advocate
OKYO H2'25 Earnings: revenue estimate is 0 USD - TradingView
OKYO Pharma Shares Edge Higher as Biotech Momentum BuildsMFI Overbought - The Legal Advocate
OKYO Pharma expands scientific advisory board with cornea expertICYMI - Proactive financial news
OKYO Pharma Ltd (OKYO) CFO details equity and option positions - Stock Titan
OKYO Pharma (OKYO) CEO discloses multiple stock option positions - Stock Titan
What Makes OKYO Pharma (OKYO) a New Buy Stock - Yahoo Finance
Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board - VisionMonday.com
OKYO Pharma adds Marta Sacchetti to scientific advisory board By Investing.com - Investing.com India
OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com - Investing.com South Africa
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment - Proactive financial news
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board - Yahoo! Finance Canada
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain - TipRanks
OKYO Pharma adds Marta Sacchetti to scientific advisory board - Investing.com
OKYO Pharma appoints Marta Sacchetti to advisory board - Investing.com
OKYO Pharma (OKYO) deepens NCP program with new advisory board expert - Stock Titan
OKYO Pharma Limited Expands Scientific Advisory Board with Appointment of Marta Sacchetti - marketscreener.com
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD - GlobeNewswire
Point72 and Steven A. Cohen report 0% stake in OKYO (NASDAQ: OKYO) - Stock Titan
Woodline Partners reports 7.0% stake in OKYO Pharma (NASDAQ: OKYO) - Stock Titan
Sirenia Capital (OKYO) files Schedule 13G reporting 7.7% ownership - Stock Titan
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):